Clinical Trial Update: Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravesical gemcitabine and docetaxel for BCG-naïve non-muscle invasive bladder cancer; results have been posted and the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Urothelial Carcinoma Bladder, Bladder Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-09-13